Inclusion Criteria:  Female aged 18- 45; Meet Rotterdam criteria; overweight/obesity,BMI≥25kg/m2  Exclusion Criteria:  Those who are allergic to the active ingredients of GLP-1 receptor agonists or any other excipients; patients with a history or family history of medullary thyroid carcinoma; patients with type 2 multiple endocrine tumor syndrome; Patients with type 1 or type 2 diabetes or diabetic ketoacidosis; Pregnancy, planned pregnancy and breastfeeding women, children; Uncontrolled hypertension (systolic/diastolic blood pressure is 140/90 mmHg); Active heart disease occurred within 3 months; Inflammatory bowel disease, diabetic gastritis or other serious gastrointestinal diseases; Liver disease, AST or ALT level is twice higher than the upper limit of normal; Kidney disease, creatinine clearance rate is less than 60mL/min; Active or untreated malignant tumors; Acute or chronic pancreatitis; Hemoglobinopathies; hemolytic or chronic anemia; Severe hypoglycemia occurred twice or more within 6 months; Eliminate the use of any drugs that may interfere with the test results (insulin, α-glucosidase inhibitor, megtinib, DPP-4 inhibitor, GLP-1 receptor agonist or rosiglitazone) Have received surgical treatment for obesity; Smoking or using any nicotine product; drinking alcohol Expect lifestyle changes (such as diet, exercise, or sleep patterns) during the trial. Currently or recently participating in another clinical trial.